Elanco Animal Health (NYSE:ELAN – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.880-0.960 for the period, compared to the consensus estimate of 0.940. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY24 guidance to $0.88-0.96 EPS.
Elanco Animal Health Price Performance
Shares of NYSE:ELAN traded up $0.05 during trading on Friday, reaching $13.04. The company had a trading volume of 4,922,213 shares, compared to its average volume of 4,884,853. The company has a fifty day moving average of $15.02 and a two-hundred day moving average of $15.38. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $6.44 billion, a P/E ratio of -4.92, a price-to-earnings-growth ratio of 1.27 and a beta of 1.42. Elanco Animal Health has a 12 month low of $8.52 and a 12 month high of $18.80.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the business earned $0.18 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities research analysts forecast that Elanco Animal Health will post 0.93 earnings per share for the current year.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on ELAN
Insider Activity at Elanco Animal Health
In other Elanco Animal Health news, Director William F. Doyle bought 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were bought at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the purchase, the director now directly owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is currently owned by company insiders.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What is the Nikkei 225 index?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Investing in Construction Stocks
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.